339 studies found for:    B-51
Show Display Options
Rank Status Study
1 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
2 Completed A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.
Conditions: Cancer;   Neoplasm
Intervention: Biological: NY-ESO-1b peptide plus CpG 7909 and Montanide ISA-51
3 Completed Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Condition: Malaria, Vivax
Interventions: Drug: Peptides (N,R&C) formulated in Montanide ISA 720;   Drug: Peptides (N,R&C) formulated in Montanide ISA 51;   Other: Placebo
4 Not yet recruiting Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
Condition: Chronic Hepatitis B
Interventions: Drug: Telbivudine;   Drug: Placebo
5 Terminated
Has Results
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Condition: Leukemia
Interventions: Biological: Peptide Vaccine (PR1 Peptide);   Drug: Peginterferon alfa-2b;   Drug: Imatinib;   Drug: GM-CSF
6 Completed Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
Condition: Influenza
Interventions: Biological: DNA vaccine;   Biological: TIV
7 Terminated A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
Conditions: Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   B Cell Malignancies
Intervention: Biological: WT1 derived peptides
8 Recruiting Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
9 Recruiting Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Condition: Chronic Hepatitis B
Interventions: Drug: Telbivudine 600mg;   Drug: Tenofovir disoproxil fumarate 300mg
10 Terminated Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Condition: Melanoma
Interventions: Biological: Immunological peptides and immunological adjuvants;   Biological: HLA-A2 peptides;   Biological: Montanide ISA51;   Biological: IMP321
11 Active, not recruiting Cognitive Changes Associated With Breast Cancer Treatment
Conditions: Breast Cancer;   Cognitive Side Effects of Cancer Treatments;   Stage I, II and III A Breast Cancer
Intervention: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
12 Not yet recruiting Vaccination of High Risk Breast Cancer Patients
Condition: Breast Neoplasms
Intervention: Biological: Chemovax
13 Active, not recruiting A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant
Condition: Hepatitis B
Intervention: Drug: Zutectra
14 Active, not recruiting Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
Condition: Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Interventions: Biological: humanised monoclonal antibody, veltuzumab;   Biological: humanised monoclonal antibody epratuzumab;   Biological: humanised monoclonal antibodies veltuzumab and epratuzumab
15 Active, not recruiting Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Condition: Tumors
Interventions: Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod;   Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
16 Unknown 
Has Results
A Study to Compare Tenofovir Versus Hepsera (Adefovir) for the Treatment of Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir disoproxil fumarate;   Drug: adefovir dipivoxil
17 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
18 Completed Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)
Condition: Dermatitis
Interventions: Other: KLH 0.1 mg;   Other: KLH 5 mg;   Other: PBS (0.1 mL);   Other: Tuberculin PPD
19 Completed
Has Results
Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children
Condition: Hepatitis B
Intervention: Biological: Engerix™-B
20 Unknown 
Has Results
A Study to Compare Tenofovir Versus Hepsera (Adefovir) for the Treatment of HBeAg Negative Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir DF (TDF) 300 mg;   Drug: Double-blind adefovir dipivoxil (ADV) 10 mg (switch to open-label TDF 300 mg post Week 48)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years